Earth Science Tech Inc (OTCMKTS:ETST) is a micro-cap stock exploding onto the MJ trading scene with a monster move in recent days. The company has been extremely active in getting the word out and expanding awareness, and it’s clearly been paying off. In recent days, we’ve heard from the company on two major themes: new talent build on the advisory board, with four new scientists and doctors joining the team, and word that its new wholly owned subsidiary, Cannabis Therapeutics, Inc. will be releasing new Cannabinoid-based Drugs and Nutraceuticals.
The action has been wild. The chart shows more than 360% during the past month in terms of shareholder gains in ETST stock. What’s more, the listing has witnessed a pop in interest, as transaction volume levels have recently pushed greater than 850% beyond what we have been seeing over the larger time frame. This should not be overlooked with a float in play that’s tiny — of 4.1M shares. It’s something the veterans know to key on: with such a tight trading float, this kind of ramping interest can force a supply-shock squeeze. Since we last covered the name, ETST stock has moved 154.5% higher.
Earth Science Tech Inc (OTCMKTS:ETST) bills itself as a unique Biotechnology company focused on delivering cutting edge Nutraceuticals, Bioceuticals and Dietary Supplements designed for excellence in the areas of Health, Wellness, Sports and Alternative Medicine and to improving the quality of life for Consumers Worldwide.
ETST is also dedicated to providing Natural Alternatives to prescription medications through Nutritional Supplements and Dietary Supplements that help improve common disorders and illnesses. This may include products such as CBD (Cannabidiol) as a natural constituent of Hemp Oil, Vitamins, Minerals, Herbs, Botanicals, Personal Care Products, Homeopathies, Functional Foods and other products.
These products may be in various formulations and delivery systems including (but not limited to) capsules, tablets, soft gels, chewables, liquids, creams, sprays, powders, and whole herbs.
According to company materials, “Earth Science Pharmaceutical, Inc. is a wholly owned subsidiary of Earth Science Tech, Inc (ETST). Earth Science Pharmaceutical is focused on becoming a world leader in the development of low cost, non-invasive diagnostic tools, medical devices, testing processes and vaccines for STIs (Sexually Transmitted Infections and/or Diseases), as well developing new advanced formulated cannabis CBD nutraceuticals and 2 Cannabis CBD-based pharmaceutical drugs under its cannabis CBD patent, IP and technology. Earth Science Pharmaceutical CEO, Dr. Michel Aubé, a renowned scientist, is committed to help grow ETST in the medical and pharmaceutical industry.”
Find out when ETST stock reaches critical levels. Subscribe to OracleDispatch.com Right Now by entering your Email in the box below.
The former of the two recent press releases seems far more substantive.
According to the release, “Cannabis Therapeutics, Inc. will begin by inventing & launching Two (2) New Cannabinoid-based Pharmaceutical drugs and Three (3) New Advanced Cannabinoid-based Nutraceutical products using Earth Science Tech’s existing Cannabis CBD Patent, IP, Invention, Technology and future Technology. ETST’s International Application (PCT) for its Provisional Patent named “Cannabidiol Compositions Including Mixtures and Uses Thereof” was filed on October 8th, 2015 in regards to its Cannabis Hemp CBD (Cannabidiol) Oil. This application claims the benefit of ETST U.S. Provisional Application N. 62/061,577, filed October 8, 2014 and ETST U.S. Provisional Application No. 62/102,538, filed January 12, 2015.”
CEO of Cannabis Therapeutics, Inc., Dr. Michel Aube, stated, “I am very enthusiastic about Cannabis Therapeutics position in the cannabis industry to become a leader in cannabinoid research and development. Our imminent new developments and efforts have the potential to expedite our numerous upcoming cannabis cannabinoid-based therapeutic products to help aid people with certain conditions and disorders worldwide, in the later part of 2017. We are focused on cannabinoid-based therapeutic drugs, functional foods and nutraceuticals (retail consumer markets worldwide). We look to announce later this week a New Scientific Advisory Board which will include myself, Dr. Michel Aube, as the Chairman of the Advisory board to Cannabis Therapeutics, Inc. as well as other World Class Scientists. ETST is extremely fortunate to have attracted world leaders to our executive leadership team and Board of Advisors. All of them are contributing their passion, time and expertise to the development of Cannabis Therapeutics unique cannabinoid-based products and solutions. Cannabis Therapeutics goal is to help advance the cannabis-cannabinoid healthcare industry and have a positive impact on the wellbeing of humans worldwide.”
Currently trading at a market capitalization of $112.5M, ETST has virtually no cash on the books, which compares with virtually no total current liabilities. ETST is pulling in trailing 12-month revenues of $496K. However, the company is seeing declines on the top line on a quarterly y/y basis, with revenues falling at -28.5%. You can bet we will update this one again as new information comes into view. For continuing coverage on shares of ETST stock, as well as our other hot stock picks, sign up for our free newsletter today and get our next hot stock pick!
